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angiotensin-(1-7) forming enzymes and receptors.
Background. Angiotensin-converting enzyme (ACE)2, a ho-
mologue of ACE, which is insensitive to ACE inhibitors and
forms angiotensin-(1-7) [Ang-(1-7)] from angiotensin II (Ang
II) with high efficiency was investigated in response to chronic
blockade with lisinopril, losartan, and both drugs combined.
Methods. Thirty-six adult Lewis rats were assigned to receive
these medications in their drinking water for 2 weeks while their
arterial pressure, water intake, and urine volume were recorded
throughout the study. Measures of renal excretory variables in-
cluded assessing excretion rates of angiotensin I (Ang I), Ang II
and Ang-(1-7) while blood collected at the completion of the
study was used for measures of plasma angiotensin concentra-
tions. Samples from renal cortex were assayed for renin, an-
giotensinogen (Aogen), neprilysin, angiotensin types 1 and 2
(AT1 and AT2) and mas receptor mRNAs by semiquantitative
reverse transcriptase (RT) real-time polymerase chain reaction
(PCR). ACE2 activity was determined as the rate of Ang II
conversion into Ang-(1-7).
Results. Comparable blood pressure reductions were ob-
tained in rats medicated with either lisinopril or losartan,
whereas both drugs produced a greater decrease in arterial pres-
sure. Polyuria was recorded in all three forms of treatment as-
sociated with reduced osmolality but no changes in creatinine
excretion. Lisinopril augmented plasma levels and urinary ex-
cretion rates of Ang I and Ang-(1-7), while plasma Ang II was
reduced with no effect on urinary Ang II. Losartan produced
similar changes in plasma and urinary Ang-(1-7) but increased
plasma Ang II without changing urinary Ang II excretion. Com-
bination therapy mimicked the effects obtained with lisinopril
on plasma and urinary Ang I and Ang-(1-7) levels. Renal cortex
Aogen mRNA increased in rats medicated with either lisino-
pril or the combination, whereas all three treatments produced
a robust increase in renal renin mRNA. In contrast, ACE,
ACE2, neprilysin, AT1, and mas receptor mRNAs remained
unchanged with all three treatments. Renal cortex ACE2 activ-
ity was significantly augmented in rats medicated with lisinopril
or losartan but not changed in those given the combination.
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Conclusion. Our data revealed a role for ACE2 in Ang-(1-7)
formation from Ang II in the kidney of normotensive rats as
primarily reflected by the increased ACE2 activity measured in
renal membranes from the kidney of rats given either lisino-
pril or losartan. The data further indicate that increased levels
of Ang-(1-7) in the urine of animals after ACE inhibition or
AT1 receptor blockade reflect an intrarenal formation of the
heptapeptide.
As the newest homologue of angiotensin-converting
enzyme (ACE), ACE2 has emerged as a novel site for
therapeutic intervention within the cascade of the renin-
angiotensin system (RAS) since the enzyme has a sub-
strate preference for hydrolyzing angiotensin II (Ang II)
into the vasodilator and antiproliferative peptide,
angiotensin-(1-7) [Ang-(1–7)] [1]. As reviewed elsewhere
[2], previous studies from our laboratory [3–7] showed
that ACE2 functions as a component of the counterregu-
latory mechanism through which Ang-(1-7) opposes the
effects of Ang II on blood pressure and cellular growth, as
well as exerting important antihypertensive actions. The
importance of ACE2 in cardiovascular regulation became
apparent in studies showing that ACE2 mRNA and pro-
tein were reduced in the kidney of experimental models
of hypertension while in ACE2 knockout mice reduced
left ventricular contractility and left ventricular dilation
could be rescued by crossing these animals with the ACE
knockout mouse [4].
The abundance of ACE2 in the heart led us to investi-
gate its role in cardiac function, particularly since previ-
ous experiments showed that Ang-(1-7), solely localized
in rat cardiac myocytes [8], exerted important cardiopro-
tective actions in terms of reversal of cardiac hypertrophy
and cardiac dysfunction [7, 9]. Furthermore, both inhibi-
tion of Ang II synthesis as well as blockade of Ang II re-
ceptors increased cardiac ACE2 mRNA as well as ACE2
activity, determined as the rate of Ang II conversion into
Ang-(1-7) in isolated cardiac membranes from the same
animals [6].
To assess the effect of interruption of the pressor and
proliferative arm of the RAS on the genes, proteins, and
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receptors constituting the axis that opposes the activity of
Ang II, we measured the effects of chronic administration
of lisinopril, losartan, or both agents on the components
of the RAS within the kidney of Lewis normotensive rats.
The resultant effect of these treatments on the enzymes
that participate in the renal formation of Ang-(1-7) from
either Ang I (neprilysin) or Ang II (ACE2) are a focus of
these studies since previous experiments indicated that
ACE inhibition and angiotensin type 1 (AT1) receptor
blockade augmented cardiac and vascular ACE2 gene
expression or activity [6, 7, 10]. Data on the effect of these
treatments on cardiac ACE2 mRNA and ACE2 activity
are reported elsewhere [6].
METHODS
Animals
Experiments were conducted in male Lewis rats (270
to 280 g) (Charles River Laboratories, Wilmington, MA,
USA) housed in individual cages (12-hour light/dark cy-
cle) with ad libitum access to rat chow and tap water
using procedures approved by our Institutional Animal
Care and Use Committee.
Experimental protocol
Thirty-six normotensive rats (age range 8 to 10 weeks)
were randomly assigned to drink either tap water (ve-
hicle) (N = 12) or tap-water to which lisinopril (10 mg/
kg/day) (N = 8), losartan (10 mg/kg/day) (N = 8), or both
drugs [same doses (N = 8)] was added to their drinking
water for 12 consecutive days. Rats were housed individ-
ually in metabolic cages for 24-hour collection of urine
both before and throughout the study.
During the treatment period, tail-cuff systolic blood
pressure was determined for 3 days before and three
times weekly after initiation of the treatments. Two weeks
after completion of the treatment regimens, rats were
anesthetized with halothane (1.5%) (Halocarbon Labo-
ratories, River Edge, NJ, USA) for direct measurements
of arterial pressure and heart rate using a catheter-tip
pressure transducer inserted into a carotid artery (Model
SPR-671) (Millar Instrument Co., Houston, TX, USA).
A 5 mL sample of arterial blood was obtained for bio-
chemical measurements. Cardiopulmonary excision was
done in deeply anesthetized rats and the kidneys were re-
moved for semiquantitative determinations of RAS gene
expression.
Biochemistry
Blood was collected into chilled tubes containing a
mixture of peptidase inhibitors: 25 mmol/L ethylenedi-
aminetetraacetic acid (EDTA), 0.44 mmol/L 1,20-ortho-
phenanthrolene monohydrate (Sigma Chemical Co., St.
Louis, MO, USA), 1 mmol/L sodium para-chloromercuri-
benzoate, and 3 lmol/L WFML (rat renin inhibitor
acetyl-His-Pro-Phe-Val-Statine-Leu-Phe) (ANASPEC).
After 30 minutes on ice, blood cells were isolated by cen-
trifugation at 3000 rpm for 20 minutes, and aliquots of
either plasma or serum were stored at −80◦C until use.
Frozen tissues were rapidly weighed and homogenized
for later assay as described elsewhere [7]. Plasma and
urinary concentrations of angiotensin peptides were mea-
sured by radioimmunoassay as documented elsewhere
[7, 11].
Serum ACE activity was determined by incubation of
the sample with radiolabeled 3H-Hip-Gly-Gly (pH 8.0)
for 1 hour at 37◦C. The intra-assay variation was 3.9% and
the interassay variation averaged 5.9%. ACE2 activity
was quantified as the rate of exogenous 125I-Ang II con-
version to 125I-Ang-(1-7) in kidney membranes isolated
from the renal cortex using procedures adapted from our
previous study in rat heart [6]. The tissue was weighed and
homogenized in 10 mmol/L Hepes, pH 7.4, 120 mmol/L
NaCl, and 10 lmol/L ZnCl2. The homogenate was subject
to centrifugation at 30,000g for 20 minutes. The super-
natant was removed, the membranes were resuspended
in the above buffer containing 0.5% Triton X-100, and
incubated overnight on ice at 4◦C. Following centrifuga-
tion, the soluble portion was incubated with 125I-Ang II
(2 × 106 cpm) (2200 Curies/mmol) in the Hepes buffer
containing 10 lmol/L of amastatin, bestatin, SCH39370
(neprilysin inhibitor), chymostatin, lisinopril, benzyl suc-
cinate, and Z-prolyl prolinal (ZPP) at 37◦C from 10 to
120 minutes and the reaction terminated by addition of
1% phosphoric acid. 125I-Ang II was iodinated by the
Chloramine T method and purified by high-performance
liquid chromatography (HPLC). The samples were sub-
jected to centrifugation and the supernatants were fil-
tered through a 0.22 l membrane prior to HPLC analysis.
Ang-(1-7) was resolved from Ang II on a Shimadzu
(Kyoto, Japan) reverse-phase HPLC equipped with a Wa-
ters NovaPak C18 column (2.1 × 150 mm) (Milford, MA,
USA). We employed a linear gradient from 10% to 25%
mobile phase B for 20 minutes and isocratic at 25% for
15 minutes at a flow rate of 0.35 mL/min at ambient
temperature. The solvent system consisted of 0.1% phos-
phoric acid (mobile phase A) and 80% acetonitrile/0.1%
phosphoric acid (mobile phase B) [12]. The eluted ra-
dioactive peaks were identified using an in-line c detec-
tor (BioScan, Washington, DC, USA) and the data were
acquired and analyzed with Shimadzu version 7.2.1 ac-
quisition software. ACE2 activity was expressed as the
amount of Ang-(1-7) generated per minute per mg pro-
tein that was inhibited by addition of 10 lmol/L of the
ACE2 inhibitor, MLN-4760 [13].
RNA isolation and reverse transcriptase (RT)/real-time
polymerase chain reaction (PCR)
RNA was isolated from kidney tissue, using the Trizol
reagent (Gibco Invitrogen, Carlsbad, CA, USA), as
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Fig. 1. Group averages of tail-cuff systolic
blood pressure determinations in conscious
Lewis normotensive rats before and after the
completion of 2 weeks of oral administration
of vehicle, lisinopril, losartan, or both drugs
in combination. Values are means ± SE. ∗P <
0.05 compared to their respective value before
initiation of the medications. P value within
graph denotes statistical difference between
rats medicated with losartan or combination
therapy.
directed by the manufacturer. The RNA concentration
and integrity were assessed using an Agilent 2100
Bioanalyzer with an RNA 6000 Nano LabChip (Agilent
Technologies, Palo Alto, CA, USA). Approximately
1 lg of total RNA was reverse transcribed using AMV
reverse transcriptase in a 20 lL reaction mixture
containing deoxyribonucleotides, random hexamers
and RNase inhibitor in RT buffer. Heating the RT
reaction product at 95◦C terminated the reaction. For
real-time PCR, 2 lL of the resultant cDNA was added
to TaqMan(TM) Universal PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) with the appropriate
gene-specific primer/probe set and amplification was
performed on an ABI 7000 Sequence Detection System.
The primer/probe sets were purchased from Applied
Biosystems with the exception of ACE2 (forward primer
5′-CCCAGAGAACAGTGGACCAAAA-3′; reverse
primer 5′-GCTCCACCACACCAACGAT-3′; and probe
5′-FAM-CTCCCGCTTCATCTCC-NFQ-3′) and mas
(forward primer 5′-TTCATAGCCATCCTCAGCTTCT
TG-3′; reverse primer 5′-GTTCTTCCGTATCTTCACC
ACCAA-3′; and probe 5′-FAM-TTCACTCCGCTCA
TGTTAG-NFQ-3′). The mixtures were heated at 50◦C
for 2 minutes, at 95◦C for 10 minutes followed by
40 cycles at 95◦C for 15 seconds and 60◦C for 1 minute.
All reactions were performed in triplicate and 18S
ribosomal RNA, amplified using the TaqMan Ribosomal
RNA Control Kit (Applied Biosystems), served as
an internal control. The results were quantified as Ct
values, where Ct is defined as the threshold cycle of
PCR at which the amplified product is first detected,
and expressed as relative gene expression (the ratio of
target/18S rRNA control).
Statistical analysis
All values are expressed as mean ± SEM. One-way
analysis of variance (ANOVA) followed by either the
Bonferroni or the two-tailed Student t tests was used for
comparing the differences at a P value <0.05.
RESULTS
Twelve-day administration of the drugs either alone
or in combination produced significant decreases in sys-
tolic blood pressure, more pronounced in rats medicated
with the combination of lisinopril-losartan (Fig. 1). Direct
measurements of mean arterial pressure at the end of the
study in the anesthetized rats confirmed the observations
obtained in conscious animals. None of the treatments
had an effect on heart rate.
As demonstrated elsewhere [6, 14, 15], rats given lisino-
pril increased plasma Ang I and Ang-(1-7) levels by
an average of 1486% and 170%, respectively, whereas
plasma Ang II and ACE were reduced by an average of
56% and 93%, respectively, compared to vehicle-treated
rats (Table 1). Losartan treatment was associated with
increases in plasma Ang I comparable to those found
in lisinopril-treated rats. In addition, losartan stimulated
large increases in plasma Ang II but not changes in plasma
Ang-(1-7) and ACE activity (Table 1). Combination ther-
apy obtunded but did not eliminate the significant rise in
plasma Ang I levels, reduced Ang II levels to values below
those found in vehicle but not lisinopril-treated rats, and
increased plasma Ang-(1-7) concentrations above those
found in rats given losartan alone (Table 1). ACE activity
in rats given combination therapy was suppressed to an
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Table 1. Profile of plasma angiotensin peptides and angiotensin-converting enzyme (ACE) activity changes by treatment groups
Variables Vehicle Lisinopril Losartan Combination
Angiotensin I fmol/mL 94 ± 26 1397 ± 171 909 ± 89a 433 ± 104a,b
P value < 0.001 0.001 0.01
Angiotensin II fmol/mL 54 ± 9 24 ± 6 332 ± 50a 22 ± 6b
P value < 0.05 0.001 0.05
Angiotensin-(1-7) fmol/mL 46 ± 10 78 ± 11 51 ± 9 89 ± 7b
P value< 0.05 NS 0.01
Angiotensin-converting enzyme 57.9 ± 4.8 3.8 ± 0.1 49.9 ± 4.0a 4.2 ± 0.3b
activity nmol/min/mL
P value< 0.001 NS 0.001
Data are means ± SE. P value denotes statistical difference versus rats medicated with the vehicle.
aP < 0.05 compared to lisinopril; bP < 0.05 compared to losartan.
Table 2. Effects of drug treatments on renal function variables
Variables Vehicle Lisinopril Losartan Combination
Water intake mL 26.70 ± 1.06 35.66 ± 1.48 26.31 ± 1.13a 40.26 ± 2.01b
P value < 0.001 NS 0.001
Urinary output mL 9.22 ± 0.64 21.33 ± 0.94 12.96 ± 0.65a 15.26 ± 1.16b
P value < 0.001 0.01 0.001
Urine osmolality mOsm/mL 2431 ± 140 928 ± 158 1850 ± 110a 1424 ± 167b
P value< 0.001 0.01 0.001
Sodium excretion mEq/24 hours 1.90 ± 0.21 1.99 ± 0.69 1.70 ± 0.07 1.63 ± 0.20
P value< NS NS NS
Potassium excretion mEq/24 hours 3.68 ± 0.28 3.28 ± 0.45 4.32 ± 0.19 3.21 ± 0.32
P value < NS NS NS
Creatinine excretion mg/24 hours 11.56 ± 1.17 9.93 ± 1.77 12.65 ± 0.80 10.44 ± 0.97
P value < NS NS NS
Data are means ± SE. P value denotes statistical difference versus rats medicated with the vehicle.
aP < 0.05 compared to lisinopril; bP < 0.05 compared to losartan.
amount not different than that found in rats given lisino-
pril (Table 1).
Table 2 shows that polydipsia associated with hyposmo-
lar polyuria and no differences in either urinary Na+ and
K+ excretion accompanied the administration of lisino-
pril. Although water intake was not changed in rats given
losartan, these animals displayed increased urinary out-
put and reduced urinary osmolality. Urinary excretion
of Na+ and K+ in losartan-treated rats was not changed
when compared to vehicle-treated controls (Table 2).
Combination therapy mimicked the effect observed in
rats medicated with lisinopril. None of the treatments
caused significant changes in urinary creatinine excretion
(Table 2).
Figure 2 illustrates the effect of the various treatments
on urinary excretion rates of Ang I, Ang II, and Ang-
(1-7). The patterns of urinary excretion of angiotensin
peptides in Lewis rats do not differ from those previously
reported for normotensive Sprague-Dawley rats [16] or
spontaneously hypertensive rats given a combined ACE
and neprilysin inhibitor [11]. Administration of an ACE
inhibitor or the Ang II receptor antagonist was associated
with augmented excretion rates of Ang I and Ang-(1-7)
but not Ang II. In addition, the average values of urinary
Ang-(1-7) excretion determined on the last day of the
treatment period correlated with plasma concentrations
of Ang I (r = 0.59, P < 0.001) and Ang-(1-7) (r = 0.55,
P < 0.001).
Hemodynamic and renal excretory changes observed
with the various protocols were associated only in part
with changes in the expression of renal RAS genes
(Table 3). All three treatments increased kidney cortex
renin mRNA while angiotensinogen mRNA increased
only in rats medicated with lisinopril or combination
therapy. In contrast, ACE, neprilysin, ACE2, AT1, and
mas receptor mRNAs were not changed by the treat-
ments. ACE2 activity increased in the renal cortex of rats
medicated with either lisinopril or losartan while ACE2
activity remained unchanged in rats given the combina-
tion therapy (Fig. 3). The increased ACE2 activity asso-
ciated with treatment with either lisinopril or losartan
correlated significantly with 24-hour urinary excretion
rates of Ang I (r = 0.57, P < 0.001) and Ang-(1–7) (r =
0.49, P < 0.02) as well as both plasma concentrations of
Ang I (r = 0.68, P < 0.001) and Ang-(1–7) (r = 0.54,
P < 0.01).
DISCUSSION
In the current study, we document for the first time the
comparative effect of inhibition of Ang II synthesis ver-
sus Ang II receptor blockade, alone or in combination, on
Ferrario et al: Renal angiotensin peptides 2193
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Fig. 2. Effects of the various treatments on urinary excretion rates of
angiotensin I (Ang I), angiotensin II (Ang II), and angiotensin-(1-7)
[Ang-(1-7)]. B is baseline. Values are means ± SE. ∗P < 0.05 compared
to the corresponding baseline values; ∗∗P < 0.05 compared to animals
medicated with lisinopril.
renal excretory variables and expression of the genes en-
coding the active peptides and receptors of the RAS in the
kidney of normotensive Lewis rats. The primary question
we addressed in these experiments was whether adminis-
tration of either lisinopril or losartan would modulate the
renal expression of RAS genes, especially those genes ac-
counting for the production (neprilysin and ACE2) and
metabolism (ACE) of the vasodilator peptide Ang-(1-7)
[17–19]. In agreement with previous studies [6, 16, 20],
these medications effectively reduced the contribution
of Ang II to blood pressure regulation as reflected by the
decrease in arterial pressure and associated changes in
both plasma and urinary excretion of Ang I, Ang II, and
Ang-(1-7).
Hemodynamic and renal excretion changes in Lewis
rats given the vehicle, lisinopril, losartan, or their com-
bination are similar to those reported in both Sprague-
Dawley rats [16] and essential hypertensive subjects
medicated with either captopril [21] or the dual vasopep-
tidase inhibitor omapatrilat [20]. The antihypertensive ef-
fect obtained with each agent alone or in combination
was essentially the same, although the blood pressure
of rats given combination therapy was reduced further
when compared to vehicle but not the rats medicated
with lisinopril alone. Urinary excretion rates of Ang I and
Ang-(1-7) but not Ang II were augmented by all three
treatment modalities, a finding that is consistent with a
role of Ang-(1-7) in mediating the polyuria found in the
treated animals [11, 16, 20].
Within the renal cortex, gene expression of renin
was markedly increased by all treatments, whereas an-
giotensinogen mRNA increased only in rats exposed
to blockade of ACE with lisinopril or the combination
of lisinopril/losartan. Although both monotherapy and
combination therapy caused marked increases in the uri-
nary excretion of Ang I and Ang-(1-7), ACE, ACE2,
and neprilysin mRNAs [genes of the enzyme axis reg-
ulating Ang-(1-7) formation and metabolism] did not
change compared to vehicle-treated animals. Similarly,
the treatments had no effect on the expression of AT1
and mas receptor mRNAs. On the other hand, ACE2
activity, measured as the rate of generated Ang-(1-7)
from Ang II in membranes from the renal cortex was
augmented in rats medicated with lisinopril and losar-
tan. A direct correlation of ACE2 activity with urinary
Ang I and Ang-(1-7) as well as plasma Ang I and Ang-
(1-7) in rats medicated with either lisinopril or losartan
provided evidence of its role in modulating the forma-
tion of Ang-(1-7) from Ang II. On the other hand, these
experiments underscore our previous conclusion that
the role of ACE2 in the regulation of cardiovascular
function is more complex than anticipated. As reported
by Gembardt et al [22], the effects of blockade of the
RAS on ACE2 protein and activity may be both tissue-
and species-specific. This interpretation agrees with our
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Table 3. Real-time polymerase chain reaction (PCR) measures of kidney renin-angiotensin system (RAS) genes
Kidney mRNAs Vehicle Lisinopril Losartan Combination
Renin 1.04 ± 0.12 30.79 ± 3.92 2.96 ± 0.33a 22.38 ± 2.64b
P value < 0.001 0.001 0.001
Angiotensinogen mRNA 1.08 ± 0.15 1.69 ± 0.17 1.19 ± 0.15a 1.63 ± 0.08
P value < 0.01 N.S. 0.007
Angiotensin-converting enzyme 1.09 ± 0.17 1.23 ± 0.12 1.02 ± 0.13 1.04 ± 0.15
P value < NS N.S. NS
Neprilysin 1.03 ± 0.11 1.04 ± 0.09 1.06 ± 0.16 1.14 ± 0.17
P value < NS N.S. NS
Angiotensin-converting enzyme 2 1.05 ± 0.12 1.10 ± 0.09 1.07 ± 0.16 0.99 ± 0.14
P value < NS N.S. NS
Angiotensin type 1 receptor 1.03 ± 0.13 1.33 ± 0.09 1.47 ± 0.22 1.02 ± 0.13
P value < NS N.S. NS
Angiotensin type 2 receptor Not detected Not detected Not detected Not detected
mas receptor 1.04 ± 0.12 1.07 ± 0.06 1.01 ± 0.11 0.95 ± 0.14
P value < NS NS NS
Data are means ± SE of values expressed as relative gene expression units. P value denotes statistical difference versus rats medicated with the vehicle.
aP < 0.05 compared to lisinopril; bP < 0.05 compared to losartan.
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Fig. 3. Effects of the various treatments on
angiotensin-converting enzyme (ACE)2 ac-
tivity measures determined as the rate of
angiotensin-(1-7) [Ang-(1-7)] formation from
angiotensin II (Ang II) in renal membranes
isolated from the kidney cortex. Values are
means ± SE. ∗P < 0.05 compared to the vehi-
cle group.
finding that the combination of lisinopril/losartan abro-
gated the increase in renal cortex ACE2 activity found in
animals medicated with either agent alone even though
this combination treatment continued to be associated
with increases in plasma and urinary excretion rates of
Ang I and Ang-(1-7). Additional evidence for a tissue-
specific response of both the ACE2 gene and ACE2 activ-
ity is furnished by the finding that cardiac ACE2 activity
increased in the hearts of Lewis rats medicated with the
combination of lisinopril and losartan [6].
Two distinct biochemical axis-pathways determine the
formation of Ang II and Ang-(1-7) from Ang I. Within
the first arm of the system ACE cleaves Ang II from Ang
I, whereas in most conditions, neprilysin is principally in-
volved in the formation of Ang-(1-7) from Ang I [23]. The
demonstration that ACE2 converts Ang II into Ang-(1-
7) connects downstream the two axis of the RAS system
[1, 18]. ACE2 is widely localized in cardiovascular tis-
sues mainly in the media and endothelium of large and
small arterial vessels, cardiac myocytes, and the tubular
epithelia of the kidneys [24]. In addition Leydig cells in
the rat testis, Leydig and Sertoli cells in the human testis,
and the uteroplacental complex showed positive staining
for ACE2 [25, 26]. Neoexpression of ACE2 in glomeru-
lar and peritubular capillary endothelium was reported
in biopsies obtained from patients with nephropathies of
various origins and in transplanted kidneys [27]. Tikellis
et al [28] first showed that the expression of the ACE2
mRNA was decreased in diabetic renal tubules by ap-
proximately 50% and was not influenced by treatment
with ramipril. This observation agrees with our findings
and those obtained by Lely et al [27] in human subjects.
On the other hand, we now show that inhibition of ACE
caused a 72% increase in ACE2 activity in the renal cor-
tex. The direct assessment of the functional activity of
the ACE2 gene provides a strong argument of a role for
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this enzyme in modulating intrarenal generation of Ang-
(1-7). Paralleling the effects of lisinopril on renal ACE2
activity, we also found that blockade of AT1 receptors is
associated with a 43% increase in renal ACE2 activity.
Thus, both suppression of Ang II formation or blockade
of Ang II binding to AT1 receptors increased ACE2 activ-
ity within the renal cortex. Because the increased ACE2
activity is associated with elevations in both plasma con-
centrations of Ang-(1-7) and urinary excretion rates of
Ang-(1-7), the data further underscore a functional role
of this novel ACE homologue in the formation of Ang-(1-
7) from Ang II. The significant correlations among renal
cortex ACE2 activity and plasma and urine Ang I and
Ang-(1-7) reinforced this interpretation. Additionally, Li
et al [29] recently reported that ACE2 is widely local-
ized in the tubules, glomeruli, and endothelial cells of the
rat kidney; however, they demonstrate an important role
of ACE2 in the formation of Ang-(1-7) from Ang I in
isolated proximal tubules. Previous studies using purified
preparations of ACE2 have emphasized that while Ang I
and Ang II share similar Km values for the enzyme, the
catalytic rate is far higher for Ang II than Ang I [1, 18, 30].
In addition, studies of Ang-(1-7) formation from Ang II
in human hearts confirmed the involvement of ACE2 in
the production of Ang-(1-7) [31, 32]. Because our ACE2
assay directly measured the rate of conversion of Ang
II to Ang-(1-7) in isolated membranes of the renal cor-
tex from the treated animals our results clearly implicate
ACE2 in the formation of intrarenal Ang-(1-7).
Combination therapy abrogated the increased renal
ACE2 activity obtained in rats medicated with either
agent alone. A differential effect of Ang II blockade
was previously reported by us in the heart of Lewis rats
after coronary artery ligation [6]. In those experiments,
both losartan and the combination of lisinopril and losar-
tan were associated with increased ACE2 activity, while
lisinopril therapy reduced cardiac ACE2 activity to val-
ues found in vehicle-treated rats [6]. Therefore, in both
this and in our previous study [6], the same therapeutic
agents given to the same rat strain at the same doses and
for the same period of time resulted in differential effects
on cardiac and renal ACE2 mRNAs and activity. The dif-
ferential effects on cardiac and renal ACE2 may not be
attributed to hemodynamic factors since the fall in blood
pressure obtained by single or combined administration
of lisinopril and losartan were not different between the
groups within this study or a cross-comparison with the
results reported previously [6]. These findings and those
reported elsewhere [22] suggest a tissue-specific regula-
tion of the ACE2 gene expression and protein in response
to maneuvers that alter either the formation of Ang
II or its activity. Uncoupling between gene expression
and protein is a known phenomenon as gene expres-
sion is regulated at transcription, translation, or by post-
translational modification. Furthermore, Zhong et al [33]
showed that all-trans retinoic acid up-regulated ACE2
gene expression in the heart and kidney of spontaneously
hypertensive rats, a finding that emphasizes a role of tran-
scriptional factors in modulation of ACE2 mRNA. Fur-
ther studies will be required to determine whether the
absence of changes in renal cortical mRNA compared to
cardiac mRNA in response to blockade of Ang II im-
plies a differential action of these agents on transcription
factors.
While our studies shed no light on the signaling mech-
anisms that are a stimulus for ACE2 gene expression and
protein activity, in both astrocytes and myocytes in cul-
ture we have preliminary evidence for a role of Ang II
in reducing ACE2 mRNA while the addition of Ang-(1-
7) into the medium blocks the inhibitory action of Ang
II [Gallagher, Tallant, and Ferrario, unpublished obser-
vations]. If the in vitro data can be interpolated to the
current findings, we can surmise that the combination
therapy producing a marked increase in plasma Ang-(1-
7) and suppressing Ang II formation should prevent stim-
ulation of ACE2 activity. On the other hand, additional
factors may be at play since the reduction in ACE2 activ-
ity found in animals receiving the combination therapy
was not associated with a decrease in urinary excretion
rates of Ang I or Ang-(1-7). These data suggest that re-
nal excretion of Ang-(1-7), although reflecting primarily
intrarenal formation of the peptide, may be under the
control of other Ang-(1-7) forming enzymes, as demon-
strated by us previously [11, 20]. The observation that
renal neprilysin mRNA was not changed by any of the
treatments alone or in combination does not necessarily
exclude this Ang-(1-7)–forming enzyme from participat-
ing in the increased Ang-(1-7) found in the urine of all
treatment groups since neprilysin activity was not deter-
mined in these experiments.
CONCLUSION
The lessons learned from this study are (1) renal ACE2
activity increases as a result of suppression of Ang II syn-
thesis or activity, a finding that suggests a feed forward
mechanism for the components of the RAS axis regulat-
ing the production of Ang-(1-7); (2) although our exper-
iments confirmed that ACE2 is not sensitive to blockade
of ACE, our data now show that ACE inhibition is associ-
ated with increased renal ACE2 activity; (3) the absence
of changes in renal AT1 and mas receptors with the vari-
ous treatment protocols suggests that the enzymes rather
than the receptors affect the regulation of the system in
these conditions; and (4) the experiments reported here
and those described elsewhere [34], collectively, impli-
cate increased Ang-(1-7) as a factor contributing to the
renoprotective actions of blockade of Ang II with either
ACE inhibitors or Ang II receptor blockers.
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